Literature DB >> 12614922

Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease.

Peter Schönknecht1, Johannes Pantel, Aoife Hunt, Martin Volkmann, Katharina Buerger, Harald Hampel, Johannes Schröder.   

Abstract

Cerebrospinal fluid tau protein levels are considered to be a promising marker for Alzheimer's disease (AD) and may facilitate early detection. Using the newly developed INNOTEST Phospho-Tau((181P)) kit examination of total tau and tau protein phosphorylated at threonine 181 (phospho-tau 181) revealed significantly (P<0.05) higher values in both patients with incipient and manifest AD than in controls. In patients with vascular dementia, phospho-tau 181 levels were not different from controls but were significantly lower than in patients with manifest AD. These findings suggest that total and phosphorylated tau protein may facilitate early detection and differential diagnosis of AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614922     DOI: 10.1016/s0304-3940(02)01481-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  Plasma phosphorylated-tau181 levels reflect white matter microstructural changes across Alzheimer's disease progression.

Authors:  Fardin Nabizadeh; Mahsa Pourhamzeh; Saghar Khani; Ayda Rezaei; Fatemeh Ranjbaran; Niloofar Deravi
Journal:  Metab Brain Dis       Date:  2022-01-11       Impact factor: 3.584

2.  Expert Consensus on Cognitive Dysfunction in Diabetes.

Authors:  Yan Yang; Jia-Jun Zhao; Xue-Feng Yu
Journal:  Curr Med Sci       Date:  2022-03-15

3.  Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease.

Authors:  Karl Hansson; Rahil Dahlén; Oskar Hansson; Elin Pernevik; Ross Paterson; Jonathan M Schott; Nadia Magdalinou; Henrik Zetterberg; Kaj Blennow; Johan Gobom
Journal:  Clin Mass Spectrom       Date:  2019-07-15

Review 4.  Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.

Authors:  Daniela Puzzo; Linda Lee; Agostino Palmeri; Giorgio Calabrese; Ottavio Arancio
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

5.  CSF Biomarkers Profile in CADASIL-A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder.

Authors:  Patrizia Formichi; Lucilla Parnetti; Elena Radi; Gabriele Cevenini; Maria Teresa Dotti; Antonio Federico
Journal:  Int J Alzheimers Dis       Date:  2010-08-18

6.  Biological markers and Alzheimer disease: a canadian perspective.

Authors:  Hyman M Schipper
Journal:  Int J Alzheimers Dis       Date:  2010-08-08

Review 7.  [Magnetic resonance imaging in clinical diagnosis of dementia].

Authors:  J Schröder; J Pantel; P Schönknecht; M Essig
Journal:  Radiologe       Date:  2003-07-01       Impact factor: 0.635

8.  Neuronal and Astrocytic Extracellular Vesicle Biomarkers in Blood Reflect Brain Pathology in Mouse Models of Alzheimer's Disease.

Authors:  Francheska Delgado-Peraza; Carlos J Nogueras-Ortiz; Olga Volpert; Dong Liu; Edward J Goetzl; Mark P Mattson; Nigel H Greig; Erez Eitan; Dimitrios Kapogiannis
Journal:  Cells       Date:  2021-04-23       Impact factor: 6.600

9.  CSF tau and β-amyloid as biomarkers for mild cognitive impairment.

Authors:  Harald Hampel; Kaj Blennow
Journal:  Dialogues Clin Neurosci       Date:  2004-12       Impact factor: 5.986

10.  CSF tau protein and FDG PET in patients with aging-associated cognitive decline and Alzheimer's disease.

Authors:  Aoife Hunt; Peter Schönknecht; Markus Henze; Pablo Toro; Uwe Haberkorn; Johannes Schröder
Journal:  Neuropsychiatr Dis Treat       Date:  2006-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.